Verici Dx (LSE:VRCI) Days Sales Outstanding : 182.50 (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Days Sales Outstanding?

Verici Dx's average Accounts Receivable for the six months ended in Jun. 2023 was £0.02 Mil. Verici Dx's Revenue for the six months ended in Jun. 2023 was £0.02 Mil. Hence, Verici Dx's Days Sales Outstanding for the six months ended in Jun. 2023 was 182.50.

The historical rank and industry rank for Verici Dx's Days Sales Outstanding or its related term are showing as below:

LSE:VRCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0 Med: 0 Max: 365
Current: 365

During the past 3 years, Verici Dx's highest Days Sales Outstanding was 365.00. The lowest was 0.00. And the median was 0.00.

LSE:VRCI's Days Sales Outstanding is ranked worse than
93.3% of 224 companies
in the Medical Diagnostics & Research industry
Industry Median: 69.415 vs LSE:VRCI: 365.00

Verici Dx's Days Sales Outstanding increased from Jun. 2022 (0.00) to Jun. 2023 (182.50).

Verici Dx Days Sales Outstanding Historical Data

The historical data trend for Verici Dx's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Days Sales Outstanding Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Days Sales Outstanding

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Days Sales Outstanding	-	-	-	-	182.50

Competitive Comparison of Verici Dx's Days Sales Outstanding

For the Diagnostics & Research subindustry, Verici Dx's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's Days Sales Outstanding Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Verici Dx's Days Sales Outstanding falls into.

Verici Dx Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Verici Dx's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Verici Dx's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding (Q: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (0	+	0.015)	/	1 )	/	0.015	*	365 / 2
=	0.015					/	0.015	*	365 / 2
=	182.50

Verici Dx (LSE:VRCI) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Verici Dx Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Verici Dx's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (LSE:VRCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

VRCDF:USA

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (LSE:VRCI) Headlines

No Headlines